MRC-5 ( Medical Research Council cell strain 5) is a diploid cell culture line composed of fibroblasts , originally developed from the lung tissue of a 14-week-old aborted Caucasian male fetus . The cell line was isolated by J.P. Jacobs and colleagues in September 1966 from the seventh population doubling of the original strain, and MRC-5 cells themselves are known to reach senescence in around 45 population doublings.
10-627: MRC-5 cells are currently used to produce several vaccines including for hepatitis A , varicella and polio . During the COVID-19 pandemic , anti-vaccination and anti-abortion activists believed that MRC-5 was an ingredient of the Oxford–AstraZeneca COVID-19 vaccine , citing a study from the University of Bristol. David Matthews, a co-author for this study, clarified that MRC-5 was solely used for testing purposes to determine "how
20-618: A person who has not previously received hepatitis A vaccine and who has direct contact with someone with hepatitis A should get hepatitis A vaccine within two weeks after exposure. Severe side effects are very rare. Pain at the site of injection occurs in about 15% of children and half of adults. Most hepatitis A vaccines contain inactivated virus while a few contain weakened virus. The ones with weakened virus are not recommended during pregnancy or in those with poor immune function . A few formulations combine hepatitis A with either hepatitis B or typhoid vaccine . Soreness or redness where
30-411: Is a stub . You can help Misplaced Pages by expanding it . Hepatitis A vaccine Hepatitis A vaccine is a vaccine that prevents hepatitis A . It is effective in around 95% of cases and lasts for at least twenty years and possibly a person's entire life. If given, two doses are recommended beginning after the age of one. It is given by injection into a muscle . The first hepatitis A vaccine
40-523: The Oxford vaccine behaves when it is inside a genetically normal human cell." The manufacturing of the vaccine used the HEK 293 fetal cell line, the kidney cells of an aborted or spontaneously miscarried female fetus, though the cells are filtered out of the final product. This microbiology -related article is a stub . You can help Misplaced Pages by expanding it . This article about vaccines or vaccination
50-445: The best protection. The initial dose of the vaccine should be followed up by a booster six to twelve months later. Protection against hepatitis A begins approximately two to four weeks after the initial vaccination. Protection lasts at least 15 years and is estimated to last at least 25 years if the booster is administered. A Cochrane review found that both types of vaccines offer significant protection, for at least two years using
60-477: The inactivated vaccine and at least five years with the attenuated vaccine. The review concluded that the inactivated vaccine is safe, but required more high quality evidence to assess the safety of the attenuated vaccine. Several commercial hepatitis A vaccines are available. The definition of (U)nits varies among manufacturers depending on how hepatitis A antigen is measured in their products. Cochrane review Too Many Requests If you report this error to
70-517: The shot is given, fever, headache, tiredness, or loss of appetite can happen after hepatitis A vaccine. As with any medicine, there is a very remote chance of a vaccine causing a severe allergic reaction, other serious injury, or death. Within the US, the vaccine Vaqta, developed by Maurice Hilleman and his team at Merck & Co. was licensed in 1995. The vaccine was phased in, around 1996, for children living in high-risk areas. In 1999, its usage
80-464: The virus, and people who are living in communities where an outbreak is present. Hepatitis A is the most common vaccine-preventable virus acquired during travel, so people traveling to places where the virus is common like the Indian subcontinent, Africa, Central America, South America, Asia, and Eastern Europe should be vaccinated. The vaccine is given in the muscle of the upper arm, in two doses for
90-728: Was approved in the European Union in 1991, and the United States in 1995. It is on the World Health Organization's List of Essential Medicines . The World Health Organization (WHO) recommends universal vaccination in areas where the disease is moderately common. Where the disease is very common, widespread vaccination is not recommended as all people typically develop immunity through infection during childhood. The US Centers for Disease Control and Prevention (CDC) recommends vaccinating: In addition,
100-719: Was widened to areas with elevating levels of infection. In the US as of 2007 , the vaccine is strongly recommended for all children 12 to 23 months of age in an attempt to eradicate the virus nationwide. Although the original Food and Drug Administration (FDA) license for Havrix by GlaxoSmithKline is dated 1995, it had been approved in Europe in 1991. The US Centers for Disease Control and Prevention (CDC) recommends vaccination of all children over one year of age, people whose sexual activity puts them at risk, people with chronic liver disease, people who are being treated with clotting factor concentrates, people working in close proximity to
#941058